P/B
10,5
GeneDx Holdings Corp delivers personalized and actionable health insights to inform diagnosis, direct treatment and improve drug discovery. The company is uniquely positioned to accelerate the use of genomic and large-scale clinical information to enable precision medicine as the standard of care. The company is at the forefront of transforming healthcare through its various exome and genome testing and interpretation, fueled by one of the world’s substantial rare disease data sets.
GeneDx Holdings Corp delivers personalized and actionable health insights to inform diagnosis, direct treatment and improve drug discovery. The company is uniquely positioned to accelerate the use of genomic and large-scale clinical information to enable precision medicine as the standard of care. The company is at the forefront of transforming healthcare through its various exome and genome testing and interpretation, fueled by one of the world’s substantial rare disease data sets.
$2.6B
Market Cap • 9/11/2026
2020
(6 years)
Founded
2021
(5 years ago)
IPO
NASDAQ
Listing Exchange
United States
Country
Valuation
P/S
5,7
P/EBITDA
—
P/OCF
—
P/FCF
—
P/E
—
BVPS
8,3
EPS
—
Market Cap
Market Cap
2,6B
EV
2,6B
EV/Revenue
5,7
EV/EBITDA
-39,8
EV/EBIT
-28,2
Payout
Dividend Per Share
0
Dividend Yield
0%
Buyback Yield
-5,8%
Total Yield
-5,8%
Payout
0%
Retained Earnings
-1,5B
Profitability
Gross Margin
69,4%
EBITDA Margin
—
EBIT Margin
—
Net Margin
—
D&A/EBITDA
0%
R&D/Revenue
18,4%
Capex/Revenue
6%
Capex/D&A
100,8%
Capex/OCF
-55,6%
SBC/OCF
—
% PPE
18,2%
% Goodwill
0,3%
ROE
—
ROIC
—
Growth
CAGR Revenue 5Y
16,3%
CAGR Op. Income 5Y
-26,2%
CAGR Net Income 5Y
-24%
CAGR EPS 5Y
-95,3%
Leverage
N.D./EBITDA
—
Debt/Equity
0%
Current Ratio
3,3
Quick Ratio
2,9
Interest Coverage
—
Premium
- Unrestricted access
- Unlimited data history
- Analysis videos
- Quarterly highlights
- Customizable financials table
- Ranking
- Discussions
...and much more!